LT3280416T - Ilgo veikimo injekcinių paliperidono esterių praleistų dozių dozavimo režimai - Google Patents

Ilgo veikimo injekcinių paliperidono esterių praleistų dozių dozavimo režimai

Info

Publication number
LT3280416T
LT3280416T LTEP16777058.5T LT16777058T LT3280416T LT 3280416 T LT3280416 T LT 3280416T LT 16777058 T LT16777058 T LT 16777058T LT 3280416 T LT3280416 T LT 3280416T
Authority
LT
Lithuania
Prior art keywords
long
dosing regimen
acting injectable
missed doses
injectable paliperidone
Prior art date
Application number
LTEP16777058.5T
Other languages
English (en)
Inventor
Srihari Gopal
Paulien Gerarda Maria RAVENSTIJN
Alberto Russu
Mahesh Narain Samtani
Original Assignee
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57072843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3280416(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.
Publication of LT3280416T publication Critical patent/LT3280416T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEP16777058.5T 2015-04-07 2016-03-30 Ilgo veikimo injekcinių paliperidono esterių praleistų dozių dozavimo režimai LT3280416T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144054P 2015-04-07 2015-04-07
US201562162596P 2015-05-15 2015-05-15
PCT/US2016/024841 WO2016164218A1 (en) 2015-04-07 2016-03-30 Dosing regimen for missed doses for long-acting injectable paliperidone esters

Publications (1)

Publication Number Publication Date
LT3280416T true LT3280416T (lt) 2020-06-25

Family

ID=57072843

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP20169861.0T LT3744326T (lt) 2015-04-07 2016-03-30 Dozavimo schema praleistoms ilgai veikiančių injekcinių paliperidono esterių dozėms
LTEP16777058.5T LT3280416T (lt) 2015-04-07 2016-03-30 Ilgo veikimo injekcinių paliperidono esterių praleistų dozių dozavimo režimai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP20169861.0T LT3744326T (lt) 2015-04-07 2016-03-30 Dozavimo schema praleistoms ilgai veikiančių injekcinių paliperidono esterių dozėms

Country Status (27)

Country Link
US (1) US10143693B2 (lt)
EP (3) EP3744326B1 (lt)
JP (3) JP6728221B2 (lt)
KR (3) KR102606678B1 (lt)
AU (4) AU2016244801B2 (lt)
BR (1) BR112017021383A2 (lt)
CA (2) CA2925908C (lt)
CY (1) CY1123203T1 (lt)
DK (2) DK3744326T3 (lt)
EA (1) EA037185B1 (lt)
ES (2) ES2967585T3 (lt)
FI (1) FI3744326T3 (lt)
HR (2) HRP20201027T1 (lt)
HU (2) HUE065435T2 (lt)
IL (3) IL254669B2 (lt)
LT (2) LT3744326T (lt)
MA (1) MA41917B1 (lt)
MD (2) MD3280416T2 (lt)
NZ (1) NZ735952A (lt)
PL (2) PL3744326T3 (lt)
PT (2) PT3744326T (lt)
RS (2) RS65024B1 (lt)
SI (2) SI3744326T1 (lt)
SM (2) SMT202300478T1 (lt)
TW (1) TWI694825B (lt)
UA (1) UA118732C2 (lt)
WO (1) WO2016164218A1 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65024B1 (sr) 2015-04-07 2024-01-31 Janssen Pharmaceutica Nv Dozni režim za propuštene doze injektibilnih estara paliperidona sa produženim delovanjem
ES3036965T3 (en) 2017-10-27 2025-09-25 Geneora Pharma Shijiazhuang Co Ltd Dosage regimen of paliperidone palmitate extended-release injectable suspension
JP7839162B2 (ja) 2020-11-30 2026-04-01 ヤンセン ファーマシューティカ エヌ．ベー． パルミチン酸パリペリドン製剤の再懸濁を確実にする方法
KR102794804B1 (ko) 2020-11-30 2025-04-10 얀센 파마슈티카 엔브이 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
ES2981035T3 (es) * 2020-11-30 2024-10-07 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada
MX2023006370A (es) 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.
WO2023030870A1 (en) * 2021-08-30 2023-03-09 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
KR102869809B1 (ko) 2023-11-21 2025-10-13 주식회사 엘지에너지솔루션 양극 및 이를 포함하는 전고체 전지

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
WO2006114384A1 (en) 2005-04-25 2006-11-02 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
KR102318070B1 (ko) * 2007-12-19 2021-10-27 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
WO2011042453A1 (en) * 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
BR112012010195A2 (pt) * 2009-10-30 2016-04-26 Janssen Pharmaceutica Nv regime de dosagem associado a ésteres de paliperidona injetável de longa ação
ES2456917T3 (es) * 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Formulación de implante de paliperidona
RS65024B1 (sr) 2015-04-07 2024-01-31 Janssen Pharmaceutica Nv Dozni režim za propuštene doze injektibilnih estara paliperidona sa produženim delovanjem

Also Published As

Publication number Publication date
MD3280416T2 (ro) 2020-10-31
AU2022221405A1 (en) 2022-09-15
MD3744326T2 (ro) 2024-05-31
IL309340A (en) 2024-02-01
SMT202000351T1 (it) 2020-09-10
NZ735952A (en) 2022-02-25
JP2020090498A (ja) 2020-06-11
US20170281629A1 (en) 2017-10-05
JP6728221B2 (ja) 2020-07-22
BR112017021383A2 (pt) 2018-07-03
JP2018510894A (ja) 2018-04-19
PT3744326T (pt) 2024-01-15
PL3744326T3 (pl) 2024-03-25
US10143693B2 (en) 2018-12-04
EP3744326A1 (en) 2020-12-02
JP7228503B2 (ja) 2023-02-24
KR20230162162A (ko) 2023-11-28
EP4349323A3 (en) 2024-06-12
AU2020239611A1 (en) 2020-10-15
ES2967585T3 (es) 2024-05-03
HUE049485T2 (hu) 2020-09-28
PL3280416T3 (pl) 2020-12-14
JP2021130680A (ja) 2021-09-09
SI3744326T1 (sl) 2024-02-29
EP4349323A2 (en) 2024-04-10
MA41917B1 (fr) 2020-07-29
AU2022221405B2 (en) 2024-08-01
KR102755145B1 (ko) 2025-01-14
EP3280416B1 (en) 2020-04-22
EP3280416A4 (en) 2019-01-23
LT3744326T (lt) 2023-12-27
EP3280416A1 (en) 2018-02-14
AU2016244801A1 (en) 2017-10-05
KR102606678B1 (ko) 2023-11-24
TW201642863A (zh) 2016-12-16
AU2016244801B2 (en) 2020-06-25
RS65024B1 (sr) 2024-01-31
RS60510B1 (sr) 2020-08-31
DK3744326T3 (da) 2024-02-05
NZ758246A (en) 2024-05-31
IL254669B2 (en) 2024-05-01
IL254669A0 (en) 2017-11-30
EP3744326B1 (en) 2023-12-06
SMT202300478T1 (it) 2024-01-10
IL309340B1 (en) 2026-01-01
SI3280416T1 (sl) 2020-07-31
KR20170134583A (ko) 2017-12-06
FI3744326T3 (fi) 2024-02-02
HRP20201027T1 (hr) 2020-12-11
CY1123203T1 (el) 2021-10-29
CA2925908A1 (en) 2016-10-07
AU2020239611B2 (en) 2022-07-21
KR20250013293A (ko) 2025-01-31
WO2016164218A1 (en) 2016-10-13
EA201792209A1 (ru) 2018-02-28
IL254669B1 (en) 2024-01-01
AU2024227790A1 (en) 2024-11-21
ES2802299T3 (es) 2021-01-18
HK1249047A1 (en) 2018-10-26
TWI694825B (zh) 2020-06-01
CA2925908C (en) 2020-09-01
HRP20240022T1 (hr) 2024-03-29
DK3280416T3 (da) 2020-05-11
PT3280416T (pt) 2020-06-30
IL324059A (en) 2025-12-01
UA118732C2 (uk) 2019-02-25
CA3088401A1 (en) 2016-10-07
HUE065435T2 (hu) 2024-05-28
EA037185B1 (ru) 2021-02-17
JP7422277B2 (ja) 2024-01-26

Similar Documents

Publication Publication Date Title
SI3744326T1 (sl) Shema odmerjanja za izpuščene odmerke za dolgodelujoče estre paliperidona za injiciranje
SI3347054T1 (sl) Režimi doziranja konjugatov zdravil proti TF protitelesu
IL253247B (en) Dosing regimen for madcam antagonists
IL247083B (en) dose fgh–18
IL251870A0 (en) Dosing regimens of buprenorphine
GB201521217D0 (en) Dosage regimens
GB2527169B (en) Dispensing needle for a fraction collector
IL246619A0 (en) A process for the recovery of a solid form of a pharmaceutical preparation
GB201418710D0 (en) Dosage regimen
ZA201702704B (en) Dosage regimen for pegylated interferon
EP2968458A4 (en) DOSAGE SCHEME FOR THERAPEUTIC PROCESS
ZA201800217B (en) Novel dosage regimen tiacumicin compound
GB201502126D0 (en) Dispensing needle for a fraction collector
GB201405884D0 (en) Filling apparatus for a fuel injector
GB201521216D0 (en) Dosage regimen
GB201418708D0 (en) Dosage regimen
GB201400171D0 (en) Dosage regimen